Search

Your search keyword '"PATTERSON, SCOTT"' showing total 2,274 results
Start Over Author "PATTERSON, SCOTT"
2,274 results on '"PATTERSON, SCOTT"'

10. Gee Vee

Author

Patterson, Scott

Published
2019

15. Atgatt

Author

Patterson, Scott

Published
2019

16. Too noisy!

Author

Patterson, Scott

Published
2019

18. Big chief

Author

Patterson, Scott

Published
2019

27. How tight?

Author

Patterson, Scott

Published
2019

32. Young Blood

Author

Patterson, Scott

Published
2018

34. OS-029 Analytical and clinical validation of AIM-NASH: a digital pathology tool for artificial intelligence-based measurement of non-alcoholic steatohepatitis histology

Author

Harrison, Stephen, Pulaski, Hanna, Vitali, Marlena, Manigat, Laryssa, Kaufman, Stephanie, Hou, Hypatia, Madasu, Susan, Hoffman, Sara, Stanford-Moore, Adam, Egger, Robert, Iyer, Janani, Glickman, Jonathan, Resnick, Murray, Patel, Neel, Taylor, Cristin, Mehta, Shraddha, Myers, Robert, Chung, Chuhan, Patterson, Scott, Sejling, Anne-Sophie, Minnich, Anne, Baxi, Vipul, Subramanian, Mani, Sanyal, Arun, Anstee, Quentin, Loomba, Rohit, Ratziu, Vlad, and Wack, Katy

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Good Health and Well Being, Public Health and Health Services, Gastroenterology & Hepatology, Clinical sciences
Published
2023

39. Randomized, open-label, phase 2 study of andecaliximab plus nivolumab versus nivolumab alone in advanced gastric cancer identifies biomarkers associated with survival

Author

Shah, Manish A, Cunningham, David, Metges, Jean-Philippe, Van Cutsem, Eric, Wainberg, Zev, Elboudwarej, Emon, Lin, Kai-Wen, Turner, Scott, Zavodovskaya, Marianna, Inzunza, David, Liu, Jinfeng, Patterson, Scott D, Zhou, Jingzhu, He, Jing, Thai, Dung, Bhargava, Pankaj, Brachmann, Carrie Baker, and Cantenacci, Daniel VT

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Clinical Trials and Supportive Activities, Digestive Diseases, Clinical Research, Rare Diseases, Cancer, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adult, Aged, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Female, Follow-Up Studies, Gene Expression Regulation, Neoplastic, Humans, Male, Middle Aged, Nivolumab, Prognosis, Stomach Neoplasms, Survival Rate, Transcriptome, Young Adult, Biomarkers, Clinical Trials, Phase II as Topic, Tumor, antibodies, neoplasm, Immunology, Oncology and carcinogenesis
Abstract

Matrix metalloproteinase-9 (MMP9) selectively cleaves extracellular matrix proteins contributing to tumor growth and an immunosuppressive microenvironment. This study evaluated andecaliximab (ADX), an inhibitor of MMP9, in combination with nivolumab (NIVO), for the treatment of advanced gastric cancer. Phase 2, open-label, randomized multicenter study evaluating the efficacy, safety, and pharmacodynamics of ADX+NIVO versus NIVO in patients with pretreated metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. The primary endpoint was objective response rate (ORR). Secondary endpoints included progression-free survival (PFS), overall survival (OS), and adverse events (AEs). We explored the correlation of efficacy outcomes with biomarkers. 144 patients were randomized; 141 were treated: 81% white, 69% male, median age was 61 years in the ADX+NIVO group and 62 years in the NIVO-alone group. The ORR was 10% (95% CI 4 to 19) in the ADX+NIVO group and 7% (95% CI 2 to 16) in the NIVO-alone group (OR: 1.5 (95% CI 0.4 to 6.1; p=0.8)). There was no response or survival benefit associated with adding ADX. AE rates were comparable in both treatment groups; the most common AEs were fatigue, decreased appetite, nausea, and vomiting. Programmed cell death ligand 1, interferon-γ (IFN), and intratumoral CD8+ cell density were not associated with treatment response or survival. The gene signature most correlated with shorter survival was the epithelial-to-mesenchymal gene signature; high transforming growth factor (TGF)-β fibrosis score was negatively associated with OS (p=0.036). Gene expression analysis of baseline tumors comparing long-(1+ years) and short-term (

Published
2021

40. Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis

Author

Anstee, Quentin M, Daly, Ann K, Govaere, Olivier, Cockell, Simon, Tiniakos, Dina, Bedossa, Pierre, Burt, Alastair, Oakley, Fiona, Cordell, Heather J, Day, Christopher P, Wonders, Kristy, Missier, Paolo, McTeer, Matthew, Vale, Luke, Oluboyede, Yemi, Breckons, Matt, Bossuyt, Patrick M, Zafarmand, Hadi, Vali, Yasaman, Lee, Jenny, Nieuwdorp, Max, Holleboom, Adriaan G, Verheij, Joanne, Ratziu, Vlad, Clément, Karine, Patino-Navarrete, Rafael, Pais, Raluca, Paradis, Valerie, Schuppan, Detlef, Schattenberg, Jörn M, Surabattula, Rambabu, Myneni, Sudha, Straub, Beate K, Vidal-Puig, Toni, Vacca, Michele, Rodrigues-Cuenca, Sergio, Allison, Mike, Kamzolas, Ioannis, Petsalaki, Evangelia, Campbell, Mark, Lelliott, Chris J, Davies, Susan, Orešič, Matej, Hyötyläinen, Tuulia, McGlinchey, Aiden, Mato, Jose M, Millet, Óscar, Dufour, Jean-François, Berzigotti, Annalisa, Masoodi, Mojgan, Pavlides, Michael, Harrison, Stephen, Neubauer, Stefan, Cobbold, Jeremy, Mozes, Ferenc, Akhtar, Salma, Olodo-Atitebi, Seliat, Banerjee, Rajarshi, Kelly, Matt, Shumbayawonda, Elizabeth, Dennis, Andrea, Andersson, Anneli, Wigley, Ioan, Romero-Gómez, Manuel, Gómez-González, Emilio, Ampuero, Javier, Castell, Javier, Gallego-Durán, Rocío, Fernández, Isabel, Montero-Vallejo, Rocío, Karsdal, Morten, Rasmussen, Daniel Guldager Kring, Leeming, Diana Julie, Sinisi, Antonia, Musa, Kishwar, Sandt, Estelle, Tonini, Manuela, Bugianesi, Elisabetta, Rosso, Chiara, Armandi, Angelo, Marra, Fabio, Gastaldelli, Amalia, Svegliati, Gianluca, Boursier, Jérôme, Francque, Sven, Vonghia, Luisa, Driessen, Ann, Ekstedt, Mattias, Kechagias, Stergios, Yki-Järvinen, Hannele, Porthan, Kimmo, Arola, Johanna, van Mil, Saskia, Papatheodoridis, George, Cortez-Pinto, Helena, Rodrigues, Cecilia M P, Valenti, Luca, Pelusi, Serena, Petta, Salvatore, Pennisi, Grazia, Miele, Luca, Geier, Andreas, Trautwein, Christian, Reißing, Johanna, Aithal, Guruprasad P, Francis, Susan, Palaniyappan, Naaventhan, Bradley, Christopher, Hockings, Paul, Schneider, Moritz, Newsome, Philip, Hübscher, Stefan, Wenn, David, Rosenquist, Christian, Trylesinski, Aldo, Mayo, Rebeca, Alonso, Cristina, Duffin, Kevin, Perfield, James W, Chen, Yu, Yunis, Carla, Tuthill, Theresa, Harrington, Magdalena Alicia, Miller, Melissa, Chen, Yan, McLeod, Euan James, Ross, Trenton, Bernardo, Barbara, Schölch, Corinna, Ertle, Judith, Younes, Ramy, Oldenburger, Anouk, Coxson, Harvey, Ostroff, Rachel, Alexander, Leigh, Biegel, Hannah, Kjær, Mette Skalshøi, Harder, Lea Mørch, Davidsen, Peter, Ellegaard, Jens, Balp, Maria-Magdalena, Brass, Clifford, Jennings, Lori, Martic, Miljen, Löffler, Jürgen, Applegate, Douglas, Shankar, Sudha, Torstenson, Richard, Lindén, Daniel, Fournier-Poizat, Céline, Llorca, Anne, Kalutkiewicz, Michael, Pepin, Kay, Ehman, Richard, Horan, Gerald, Ho, Gideon, Tai, Dean, Chng, Elaine, Patterson, Scott D, Billin, Andrew, Doward, Lynda, Twiss, James, Thakker, Paresh, Derdak, Zoltan, Landgren, Henrik, Lackner, Carolin, Gouw, Annette, Hytiroglou, Prodromos, Mózes, Ferenc E, Lee, Jenny A, Alzoubi, Osama, Staufer, Katharina, Trauner, Michael, Paternostro, Rafael, Stauber, Rudolf E, van Dijk, Anne-Marieke, Mak, Anne Linde, de Saint Loup, Marc, Shima, Toshihide, Gaia, Silvia, Shalimar, Lupșor-Platon, Monica, Wong, Vincent Wai-Sun, Li, Guanlin, Wong, Grace Lai-Hung, Karlas, Thomas, Wiegand, Johannes, Sebastiani, Giada, Tsochatzis, Emmanuel, Liguori, Antonio, Yoneda, Masato, Nakajima, Atsushi, Hagström, Hannes, Akbari, Camilla, Hirooka, Masashi, Chan, Wah-Kheong, Mahadeva, Sanjiv, Rajaram, Ruveena, Zheng, Ming-Hua, George, Jacob, Eslam, Mohammed, Viganò, Mauro, Ridolfo, Sofia, Aithal, Guruprasad Padur, Lee, Dae Ho, Nasr, Patrik, Cassinotto, Christophe, de Lédinghen, Victor, Mendoza, Yuly P, Noureddin, Mazen, Truong, Emily, and Harrison, Stephen A

Published
2023
Full Text
View/download PDF

41. NAFLD and NASH biomarker qualification in the LITMUS consortium – Lessons learned

Author

Rasmussen, Daniel Guldager Kring, Anstee, Quentin M., Torstenson, Richard, Golding, Bruno, Patterson, Scott D., Brass, Clifford, Thakker, Paresh, Harrison, Stephen, Billin, Andrew N., Schuppan, Detlef, Dufour, Jean-François, Andersson, Anneli, Wigley, Ioan, Shumbayawonda, Elizabeth, Dennis, Andrea, Schoelch, Corinna, Ratziu, Vlad, Yunis, Carla, Bossuyt, Patrick, and Karsdal, Morten Asser

Published
2023
Full Text
View/download PDF

42. FRI-195 Genetically determined circulating protein biomarkers and risk of advanced fibrosis

Author

Wang, Jun, primary, Cuellar-Partida, Gabriel, additional, Read, Robert W., additional, Schlauch, Karen A., additional, Elhanan, Gai, additional, Metcalf, W. James, additional, Boyette, Lisa, additional, Watkins, Timothy R., additional, Grzymski, Joseph J., additional, Patterson, Scott D., additional, Iqbal, Shahed, additional, and Billin, Andrew N., additional

Published
2024
Full Text
View/download PDF

47. Mutational landscape of gastric adenocarcinoma in Chinese: Implications for prognosis and therapy

Author

Chen, Kexin, Yang, Da, Li, Xiangchun, Sun, Baocun, Song, Fengju, Cao, Wenfeng, Brat, Daniel J, Gao, Zhibo, Li, Haixin, Liang, Han, Zhao, Yanrui, Zheng, Hong, Li, Miao, Buckner, Jan, Patterson, Scott D, Ye, Xiang, Reinhard, Christoph, Bhathena, Anahita, Joshi, Deepa, Mischel, Paul S, Croce, Carlo M, Wang, Yi Michael, Raghavakaimal, Sreekumar, Li, Hui, Lu, Xin, Pan, Yang, Chang, Han, Ba, Sujuan, Luo, Longhai, Cavenee, Webster K, Zhang, Wei, and Hao, Xishan

Subjects
Biological Sciences, Biomedical and Clinical Sciences, Genetics, Oncology and Carcinogenesis, Biotechnology, Cancer, Breast Cancer, Human Genome, Aetiology, 2.1 Biological and endogenous factors, Good Health and Well Being, Adenocarcinoma, Age Factors, Asian People, Case-Control Studies, China, DNA Mutational Analysis, Databases, Nucleic Acid, Disease-Free Survival, Female, Genome-Wide Association Study, Homologous Recombination, Humans, Male, Mutation, Neoplasm Proteins, Stomach Neoplasms, Survival Rate, clonality, exome sequencing, mutation, ERBB, BRCA2
Abstract

Gastric cancer (GC) is a highly heterogeneous disease. To identify potential clinically actionable therapeutic targets that may inform individualized treatment strategies, we performed whole-exome sequencing on 78 GCs of differing histologies and anatomic locations, as well as whole-genome sequencing on two GC cases, each with three primary tumors and two matching lymph node metastases. The data showed two distinct GC subtypes with either high-clonality (HiC) or low-clonality (LoC). The HiC subtype of intratumoral heterogeneity was associated with older age, TP53 (tumor protein P53) mutation, enriched C > G transition, and significantly shorter survival, whereas the LoC subtype was associated with younger age, ARID1A (AT rich interactive domain 1A) mutation, and significantly longer survival. Phylogenetic tree analysis of whole-genome sequencing data from multiple samples of two patients supported the clonal evolution of GC metastasis and revealed the accumulation of genetic defects that necessitate combination therapeutics. The most recurrently mutated genes, which were validated in a separate cohort of 216 cases by targeted sequencing, were members of the homologous recombination DNA repair, Wnt, and PI3K-ERBB pathways. Notably, the drugable NRG1 (neuregulin-1) and ERBB4 (V-Erb-B2 avian erythroblastic leukemia viral oncogene homolog 4) ligand-receptor pair were mutated in 10% of GC cases. Mutations of the BRCA2 (breast cancer 2, early onset) gene, found in 8% of our cohort and validated in The Cancer Genome Atlas GC cohort, were associated with significantly longer survivals. These data define distinct clinicogenetic forms of GC in the Chinese population that are characterized by specific mutation sets that can be investigated for efficacy of single and combination therapies.

Published
2015

49. Guidelines for the next 10 years of proteomics

Author

Wilkins, Marc R, Appel, Ron D, Van Eyk, Jennifer E, Chung, Maxey C M, Görg, Angelika, Hecker, Michael, Huber, Lukas A, Langen, Hanno, Link, Andrew J, Paik, Young-Ki, Patterson, Scott D, Pennington, Stephen R, Rabilloud, Thierry, Simpson, Richard J, Weiss, Walter, and Dunn, Michael J

Subjects
Quantitative Biology - Genomics
Abstract

In the last ten years, the field of proteomics has expanded at a rapid rate. A range of exciting new technology has been developed and enthusiastically applied to an enormous variety of biological questions. However, the degree of stringency required in proteomic data generation and analysis appears to have been underestimated. As a result, there are likely to be numerous published findings that are of questionable quality, requiring further confirmation and/or validation. This manuscript outlines a number of key issues in proteomic research, including those associated with experimental design, differential display and biomarker discovery, protein identification and analytical incompleteness. In an effort to set a standard that reflects current thinking on the necessary and desirable characteristics of publishable manuscripts in the field, a minimal set of guidelines for proteomics research is then described. These guidelines will serve as a set of criteria which editors of PROTEOMICS will use for assessment of future submissions to the Journal.

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results